Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
Biomarker Research volume 9, Article number: 83 (2021)
Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined “myeloid and lymphoid neoplasms with eosinophilia”. The heterogeneous nature of genomic aberrations and the promiscuity of fusion partners, may limit the diagnostic accuracy of current cytogenetics approaches. To address such technical challenges, we exploited a nanopore-based sequencing assay to screen patients with primary Eosinophilia. The comprehensive sequencing approach described here enables the identification of genomic fusion in 60 h, starting from DNA purified from whole blood.
To the Editor,
the 2016-WHO category of myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2 (MLN-Eo) is defined by an absolute, persistent, eosinophil count (AEC) ≥1500/uL . In most cases, the initial diagnostic framework relies on cytogenetics; individual molecular probes specifically targeting PDGFRα, PDGFRβ, FGFR1 or the PCM1-JAK2 fusion are employed for FISH analysis to identify the most recurrent translocations. However, owing to the promiscuous nature of the fusion events , including currently unknown partners, FISH approach has anticipated shortcomings depending on the availability of probes for known partner genes . On the other hand, RNA analysis might be more informative but it poses long turnaround times and bioinformatic challenges . In this context, we exploited the potential advantages of a long-read genome-wide nanopore sequencing (NS) to detect fusion events involving PDGFRα/β, FGFR1 and JAK2 in unamplified DNA samples .
To the purposes of the study, we sequenced 12 samples from patients with Eosinophilia (7 males, 5 females) whose familiar or secondary origin were excluded and who had stored samples collected at presentation (local ethics committee approval: #14,560). Full set of clinical and cytogenetic data were available for all the patients (Supplemental Table 1). The median age, AEC and white blood cell count at diagnosis were, respectively, 48 years (range 25-85), 1.4/L (range, 1.1-6.7) and 14.45 × 109/L (range, 7.3-105). All subjects were negative for JAK2V617F, MPLW515 or CALRexon9 mutation.
Genomic DNA was purified from whole blood and prepared for whole genome NS as previously described . Rough sequencing data were aligned to the Human Reference GRCh38 by Minimap2 (v2.17). Variant calling in the regions of interest was carried out through a read-count approach (Fig. 1 A) with Nano-GLADIATOR , and by a gapped-alignment and split-read approach (Fig. 1 B) through Sniffles .
Given the prevalence of the translocation FIP1L1-PDGFRα in MLN-Eo, we first performed a read-count analysis aimed at detecting possible interstitial deletion involving PDGFRα . A del (q12q12) was identified in 3 samples, involving 800±100Kb (sample #1), 700±100Kb (sample #2) and 900±100Kb (sample #3). Further annotation by AnnotSV  revealed the genes comprised by the reported deletions, as shown in Table 1.
Sequencing data were further analysed by Sniffles. In samples #4 and #5, chimeric reads with multiple alignment pointing were detected at a t(5;12)(q32;p13) and a t(5;14)(q32q32), respectively. The chimeric reads in sample #4 spanned from 9,394 bp to 52,545 bp, of which at least 810 bp (up to 46,423 bp) were aligned to PDGFRβ and 6,108 bp (up to 21,245 bp) to ETV6; more specifically, the clustering of chimeric reads predicted the fusion breakpoint between intron 10 of PDGFRβ (nucleotide, nt, position 15,776) and intron 4 of ETV6 (nt position 218,066). The translocation found in sample #5 was originated by the fusion between PDGFRβ intron 9 (nt position 16,372) and CCDC88C intron 24 (nt position 19,495). The chimeric read spanned 32,847 bp, where 22,736 bp were aligned to PDGFRβ and 9,111 bp to CCDC88C.
In samples #6 and #7 we found, respectively, 3 and 2 chimeric reads predicting for a t(8;13)(p11;q12). The chimeric reads in sample #6 (spanning from 16,164 bp to 15,152 bp) were composed by the FGFR1 sequence (min overlap: 678 bp – max overlap: 7,324 bp) fused to ZMYM2 (min overlap: 8,911 bp – max overlap: 25,858 bp); the fusion breakpoint was located at nucleotides 6,754 and 102,102 of FGFR1 and ZMYM2, respectively. In sample #7, the two chimeric reads (22,890 bp and 57,953 bp) were aligned to FGFR1 (by 13,483 or 21,753 bp) and to ZMYM2 (by 9,407 or 36,200 bp). The fusion breakpoint was detected between nucleotides 21,209 of FGFR1 and 89,374 of ZMYM2.
No PCM1-JAK2 fusion was detected in any samples of the cohort.
The NS screening results were in full agreement with FISH analysis (Pearson’s R2 coefficient:1) independently performed on the same samples of eosinophils collected at diagnosis. We show here that long-reads analysis facilitated the identification of the exact breakpoints of gene fusion in the 7 mutated patients, an information not provided by conventional cytogenetic approaches. The described pipeline allows to complete simultaneous genomic search for rearrangements of PDGFRα/β, FGFR1 and JAK2 in 60 h from blood sample collection, at an affordable cost, currently estimated at 500 Euros per sample. Finally, the NS long-reads sequencing of DNA enables the identification of possible unknown fusion partners by the alignment of the chimeric sequences to a reference genome.
Availability of data and materials
The datasets analyzed during the study are available at the Gene Expression Omnibus (GEO) database repository: GEO code GSE185446 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE185446).
Absolute Eosinophil Count
myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2
Fluorescence In Situ Hybridization
Shomali W, Gotlib J. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management. Am J Hematol. 2019;94(10):1149–67.
Reiter A, Gotlib J. Myeloid neoplasms with eosinophilia. Blood. The Journal of the American Society of Hematology. 2017;129(6):704–14.
Maccaferri M, Pierini V, Di Giacomo D, Zucchini P, Forghieri F, Bonacorsi G, et al. The importance of cytogenetic and molecular analyses in eosinophilia-associated myeloproliferative neoplasms: an unusual case with normal karyotype and TNIP1-PDGFRB rearrangement and overview of PDGFRB partner genes. Leukemia lymphoma. 2017;58(2):489–93.
Baer C, Muehlbacher V, Kern W, Haferlach C, Haferlach T. Molecular genetic characterization of myeloid/lymphoid neoplasms associated with eosinophilia and rearrangement of PDGFRA, PDGFRB, FGFR1 or PCM1-JAK2. Haematologica. 2018;103(8):e348.
Feng Y, Zhang Y, Ying C, Wang D, Du C. Nanopore-based fourth-generation DNA sequencing technology. Genomics Proteomics Bioinformatics. 2015;13(1):4–16.
Bartalucci N, Romagnoli S, Contini E, Marseglia G, Magi A, Guglielmelli P, et al. Long Reads, Short Time: Feasibility of Prenatal Sample Karyotyping by Nanopore Genome Sequencing. Clin Chem. 2019;65(12):1605–8.
Magi A, Bolognini D, Bartalucci N, Mingrino A, Semeraro R, Giovannini L, et al. Nano-GLADIATOR: real-time detection of copy number alterations from nanopore sequencing data. Bioinformatics. 2019.
Sedlazeck FJ, Rescheneder P, Smolka M, Fang H, Nattestad M, von Haeseler A, et al. Accurate detection of complex structural variations using single-molecule sequencing. Nat Methods. 2018;15(6):461–8.
Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348(13):1201–14.
Geoffroy V, Herenger Y, Kress A, Stoetzel C, Piton A, Dollfus H, et al. AnnotSV: an integrated tool for structural variations annotation. Bioinformatics. 2018;34(20):3572–4.
This work was supported by Associazione Italiana per la Ricerca sul Cancro (AIRC) 5 × 1000 call “Metastatic disease: the key unmet need in oncology” to MYeloid NEoplasms Research Venture AIRC (MYNERVA), project #21267; Fondazione Cassa di Risparmio di Firenze, Bando Ricerca Scientifica e Tecnologica, project #46400.
Ethics approval and consent to participate
The study was performed in compliance with the local ethics committee approval (#14,560) obtained for the AIRC-MYNERVA Project (#21,267).
Consent for publication
All the listed authors read the manuscript and approved the submitted data for publication.
AMV : member of advisory board of GSK, Incyte, Novartis, Blueprint ; speaker for Novartis, Incyte, Abbvie, BMS. PG : member of advisory board of Novartis, Abbvie. FM : member of advisory board of Novartis. CM : member of advisory board of Celgene ; member of editorial board of Dynamicon. There is no conflict of interest related to the current work to disclose for any of the other authors.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Romagnoli, S., Bartalucci, N., Gesullo, F. et al. Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2. Biomark Res 9, 83 (2021). https://doi.org/10.1186/s40364-021-00337-1
- Primary eosinophilic disorders
- Nanopore sequencing